OpenOnco
UA EN
Plan Builder Onco Wiki Tumor Board

Onco Wiki / Drug

Oxaliplatin

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

IDDRUG-OXALIPLATIN
TypeDrug
Aliases
EloxatinОксаліплатин
Statusreviewed 2026-04-26 | pending_clinical_signoff
DiseasesDIS-CRC DIS-ESOPHAGEAL DIS-GASTRIC DIS-NK-T-NASAL DIS-PDAC
SourcesSRC-ESMO-COLON-2024 SRC-NCCN-COLON-2025

Drug Facts

ClassPlatinum alkylating agent (third-generation; DACH-platinum)
MechanismDiaminocyclohexane (DACH) platinum compound. Forms intra- and inter- strand platinum-DNA adducts (preferentially N7 of guanine), bulkier than cisplatin/carboplatin adducts and recognized differently by the mismatch-repair machinery — explains partial activity in MMR-deficient tumors. Cumulative dose-dependent peripheral sensory neuropathy is the signature toxicity (acute cold-induced + chronic stocking-glove). Backbone of FOLFOX, CAPOX, FOLFIRINOX, FLOT.
Typical dosingFOLFOX (mFOLFOX6): 85 mg/m² IV over 2 h day 1 every 14 d. CAPOX (XELOX): 130 mg/m² IV over 2 h day 1 every 21 d. FOLFIRINOX: 85 mg/m² IV day 1 every 14 d. FLOT (gastric): 85 mg/m² IV day 1 every 14 d. Adjuvant colon (IDEA-supported): 3 months CAPOX or 6 months FOLFOX per stage and risk; cumulative dose target ≤780 mg/m² to limit chronic neuropathy.
Ukraine registeredTrue
NSZU reimbursedTrue
Ukraine last verified2026-04-27

Warnings

Notes

Cumulative-dose neuropathy management: stop or de-escalate at Grade 2 functional neuropathy or after ~780-1000 mg/m² regardless. Cold avoidance × 5 days post-dose (gloves, no cold drinks). IDEA trial: 3 vs 6 months adjuvant in stage III colon — for low-risk T1-3 N1, 3 months CAPOX is non-inferior with substantially less neuropathy. Calcium / magnesium infusions for neuropathy prevention NOT supported by N08CB trial — abandoned as standard.

Used By

Regimens